Loading patent…
AssigneeKymab Limited
InventorsRichard Charles Alfred Sainson, Stephen John Arkinstall, Jamie Iain Campbell, Mohammed Hanif Ali, E-Chiang Lee, Matthew John McCourt, Nikole Sandy, Cassandra Van Krinks, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Cecilia Deantonio, Stephen D. Gillies
Estimating the term…
Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
An isolated antibody that comprises a binding site for the extracellular domain of human ICOS, wherein the antibody comprises a VH domain comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:
A method of treating cancer in a patient, comprising administering to the patient
A method of treating cancer in a patient, comprising administering to the patient
Dependencies are inferred from the claim text.